×
S&P 500   3,821.84 (+0.01%)
DOW   31,089.39 (+0.46%)
QQQ   284.07 (+0.19%)
AAPL   139.77 (+1.70%)
MSFT   261.17 (+1.83%)
META   163.23 (+1.59%)
GOOGL   2,225.00 (-0.68%)
AMZN   109.21 (+1.69%)
TSLA   679.50 (-2.65%)
NVDA   154.29 (-3.46%)
NIO   21.64 (-3.22%)
BABA   115.47 (-1.10%)
AMD   77.60 (-3.94%)
MU   55.75 (-3.65%)
CGC   3.52 (-2.49%)
T   20.99 (+1.84%)
GE   63.62 (-3.43%)
F   11.52 (-2.46%)
DIS   95.65 (-0.28%)
AMC   13.49 (+0.82%)
PFE   51.23 (+1.13%)
PYPL   71.23 (-0.82%)
NFLX   177.36 (-1.25%)
S&P 500   3,821.84 (+0.01%)
DOW   31,089.39 (+0.46%)
QQQ   284.07 (+0.19%)
AAPL   139.77 (+1.70%)
MSFT   261.17 (+1.83%)
META   163.23 (+1.59%)
GOOGL   2,225.00 (-0.68%)
AMZN   109.21 (+1.69%)
TSLA   679.50 (-2.65%)
NVDA   154.29 (-3.46%)
NIO   21.64 (-3.22%)
BABA   115.47 (-1.10%)
AMD   77.60 (-3.94%)
MU   55.75 (-3.65%)
CGC   3.52 (-2.49%)
T   20.99 (+1.84%)
GE   63.62 (-3.43%)
F   11.52 (-2.46%)
DIS   95.65 (-0.28%)
AMC   13.49 (+0.82%)
PFE   51.23 (+1.13%)
PYPL   71.23 (-0.82%)
NFLX   177.36 (-1.25%)
S&P 500   3,821.84 (+0.01%)
DOW   31,089.39 (+0.46%)
QQQ   284.07 (+0.19%)
AAPL   139.77 (+1.70%)
MSFT   261.17 (+1.83%)
META   163.23 (+1.59%)
GOOGL   2,225.00 (-0.68%)
AMZN   109.21 (+1.69%)
TSLA   679.50 (-2.65%)
NVDA   154.29 (-3.46%)
NIO   21.64 (-3.22%)
BABA   115.47 (-1.10%)
AMD   77.60 (-3.94%)
MU   55.75 (-3.65%)
CGC   3.52 (-2.49%)
T   20.99 (+1.84%)
GE   63.62 (-3.43%)
F   11.52 (-2.46%)
DIS   95.65 (-0.28%)
AMC   13.49 (+0.82%)
PFE   51.23 (+1.13%)
PYPL   71.23 (-0.82%)
NFLX   177.36 (-1.25%)
S&P 500   3,821.84 (+0.01%)
DOW   31,089.39 (+0.46%)
QQQ   284.07 (+0.19%)
AAPL   139.77 (+1.70%)
MSFT   261.17 (+1.83%)
META   163.23 (+1.59%)
GOOGL   2,225.00 (-0.68%)
AMZN   109.21 (+1.69%)
TSLA   679.50 (-2.65%)
NVDA   154.29 (-3.46%)
NIO   21.64 (-3.22%)
BABA   115.47 (-1.10%)
AMD   77.60 (-3.94%)
MU   55.75 (-3.65%)
CGC   3.52 (-2.49%)
T   20.99 (+1.84%)
GE   63.62 (-3.43%)
F   11.52 (-2.46%)
DIS   95.65 (-0.28%)
AMC   13.49 (+0.82%)
PFE   51.23 (+1.13%)
PYPL   71.23 (-0.82%)
NFLX   177.36 (-1.25%)
NASDAQ:KIDS

OrthoPediatrics Stock Forecast, Price & News

$44.00
-0.61 (-1.37%)
(As of 06/29/2022 02:20 PM ET)
Add
Compare
Today's Range
$43.62
$44.17
50-Day Range
$38.50
$51.51
52-Week Range
$36.71
$73.91
Volume
1,070 shs
Average Volume
112,916 shs
Market Capitalization
$890.12 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$63.80
30 days | 90 days | 365 days | Advanced Chart

Receive KIDS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for OrthoPediatrics and its competitors with MarketBeat's FREE daily newsletter.

KIDS Stock Forecast (MarketRank)

Overall MarketRank

2.70 out of 5 stars

Medical Sector

64th out of 1,433 stocks

Surgical & Medical Instruments Industry

7th out of 137 stocks

Analyst Opinion: 3.5Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 5.0Valuation: 0.6 5 -4 -3 -2 -1 -
OrthoPediatrics logo

About OrthoPediatrics (NASDAQ:KIDS)

OrthoPediatrics Corp., a medical device company, designs, develops, and markets anatomically appropriate implants and devices for the treatment of children with orthopedic conditions in the United States and internationally. The company offers trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products. Its products comprise PediLoc, PediPlates, cannulated screws, PediFlex nail, PediNail, PediLoc tibia, anterior cruciate ligament reconstruction systems, locking cannulated blades, locking proximal femurs, Spica Tables, RESPONSE Spine systems, Bandloc, Pediguard, Pediatric Nailing Platform, Femur system, Orthex, QuickPack, and ApiFix Mid-C system. The company serves pediatric orthopedic market, as well as pediatric orthopedic surgeons and caregivers. OrthoPediatrics Corp. was founded in 2006 and is headquartered in Warsaw, Indiana.

KIDS Stock News Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:KIDS
Employees
133
Year Founded
N/A

Company Calendar

Last Earnings
11/03/2021
Today
6/29/2022
Next Earnings (Estimated)
8/03/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$63.80
High Stock Price Forecast
$77.00
Low Stock Price Forecast
$54.00
Forecasted Upside/Downside
+45.0%
Consensus Rating
Buy
Rating Score (0-4)
3
Research Coverage
5 Analysts

Profitability

Net Income
$-16.26 million
Pretax Margin
-16.11%

Debt

Sales & Book Value

Annual Sales
$98.05 million
Book Value
$11.45 per share

Miscellaneous

Free Float
14,262,000
Market Cap
$890.12 million
Optionable
Not Optionable
Beta
0.88














OrthoPediatrics Frequently Asked Questions

Should I buy or sell OrthoPediatrics stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OrthoPediatrics in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" OrthoPediatrics stock.
View analyst ratings for OrthoPediatrics
or view top-rated stocks.

What is OrthoPediatrics' stock price forecast for 2022?

5 brokerages have issued twelve-month price targets for OrthoPediatrics' shares. Their KIDS stock forecasts range from $54.00 to $77.00. On average, they predict OrthoPediatrics' share price to reach $63.80 in the next twelve months. This suggests a possible upside of 45.0% from the stock's current price.
View analysts' price targets for OrthoPediatrics
or view top-rated stocks among Wall Street analysts.

How has OrthoPediatrics' stock performed in 2022?

OrthoPediatrics' stock was trading at $59.86 at the beginning of 2022. Since then, KIDS stock has decreased by 26.5% and is now trading at $44.00.
View the best growth stocks for 2022 here
.

When is OrthoPediatrics' next earnings date?

OrthoPediatrics is scheduled to release its next quarterly earnings announcement on Wednesday, August 3rd 2022.
View our earnings forecast for OrthoPediatrics
.

How were OrthoPediatrics' earnings last quarter?

OrthoPediatrics Corp. (NASDAQ:KIDS) released its earnings results on Wednesday, November, 3rd. The company reported ($0.15) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.28) by $0.13. The firm earned $25.08 million during the quarter. OrthoPediatrics had a negative net margin of 14.98% and a negative trailing twelve-month return on equity of 7.04%.
View OrthoPediatrics' earnings history
.

What guidance has OrthoPediatrics issued on next quarter's earnings?

OrthoPediatrics issued an update on its FY 2022 earnings guidance on Tuesday, June, 28th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $125.00 million-$128.00 million, compared to the consensus revenue estimate of $123.15 million.

Who are OrthoPediatrics' key executives?

OrthoPediatrics' management team includes the following people:
  • Mr. Mark C. Throdahl, Exec. Chairman (Age 71, Pay $450.17k) (LinkedIn Profile)
  • Mr. David R. Bailey, Pres, CEO & Director (Age 43, Pay $544.69k)
  • Mr. Fred L. Hite, CFO, Principal Financial & Accounting Officer, COO and Director (Age 54, Pay $544.69k) (LinkedIn Profile)
  • Mr. Daniel J. Gerritzen, VP, Gen. Counsel & Sec. (Age 52, Pay $442.57k)
  • Mr. Gregory A. Odle, Exec. VP of Commercialization (Age 52, Pay $455.6k) (LinkedIn Profile)
  • Mr. Joseph W. Hauser, Sr. VP and GM of Trauma & Deformity Correction (Age 40, Pay $442.29k)
  • Mr. Joel Batts, Sr. VP of Science & Technology
  • Mr. Mark Karshner, Sr. VP of International Sales
  • Mr. Paul J. Mraz, Sr. VP & GM of Scoliosis

What is Mark Throdahl's approval rating as OrthoPediatrics' CEO?

15 employees have rated OrthoPediatrics CEO Mark Throdahl on Glassdoor.com. Mark Throdahl has an approval rating of 100% among OrthoPediatrics' employees. This puts Mark Throdahl in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of OrthoPediatrics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other OrthoPediatrics investors own include AbbVie (ABBV), Freeport-McMoRan (FCX), Gilead Sciences (GILD), Intel (INTC), Advanced Micro Devices (AMD), CRISPR Therapeutics (CRSP), Cisco Systems (CSCO), Walt Disney (DIS), Enterprise Products Partners (EPD) and NVIDIA (NVDA).

When did OrthoPediatrics IPO?

(KIDS) raised $52 million in an initial public offering on Thursday, October 12th 2017. The company issued 4,000,000 shares at a price of $12.00-$14.00 per share. Piper and Jaffray Stifel served as the underwriters for the IPO and William Blair and BTIG were co-managers.

What is OrthoPediatrics' stock symbol?

OrthoPediatrics trades on the NASDAQ under the ticker symbol "KIDS."

Who are OrthoPediatrics' major shareholders?

OrthoPediatrics' stock is owned by a number of retail and institutional investors. Top institutional investors include Brown Advisory Inc. (5.94%), Riverbridge Partners LLC (5.84%), BlackRock Inc. (4.61%), Vanguard Group Inc. (3.59%), Next Century Growth Investors LLC (2.65%) and Wasatch Advisors Inc. (2.39%). Company insiders that own OrthoPediatrics stock include (Reynolds) Marie C Infante, Bernie B Berry III, Bernie B Berry III, Daniel J Gerritzen, David R Bailey, David R Pelizzon, Fred Hite, Gregory A Odle, Harold Ruf, Jennifer N Pritzker, Joseph W Hauser, Mark C Throdahl, Mark C Throdahl, Stephen F Burns and Terry D Schlotterback.
View institutional ownership trends for OrthoPediatrics
.

Which major investors are selling OrthoPediatrics stock?

KIDS stock was sold by a variety of institutional investors in the last quarter, including Summit Partners Public Asset Management LLC, Lord Abbett & CO. LLC, Oak Ridge Investments LLC, Wasatch Advisors Inc., State Street Corp, Northern Trust Corp, JPMorgan Chase & Co., and Royce & Associates LP. Company insiders that have sold OrthoPediatrics company stock in the last two years include (Reynolds) Marie C Infante, Bernie B Berry III, Daniel J Gerritzen, David R Bailey, Fred Hite, Gregory A Odle, Joseph W Hauser, Mark C Throdahl, Stephen F Burns, and Terry D Schlotterback.
View insider buying and selling activity for OrthoPediatrics
or view top insider-selling stocks.

Which major investors are buying OrthoPediatrics stock?

KIDS stock was bought by a variety of institutional investors in the last quarter, including Brown Advisory Inc., Granahan Investment Management LLC, New York State Common Retirement Fund, Riverbridge Partners LLC, Invesco Ltd., Lisanti Capital Growth LLC, Dimensional Fund Advisors LP, and First Light Asset Management LLC. Company insiders that have bought OrthoPediatrics stock in the last two years include David R Pelizzon, Harold Ruf, and Jennifer N Pritzker.
View insider buying and selling activity for OrthoPediatrics
or or view top insider-buying stocks.

How do I buy shares of OrthoPediatrics?

Shares of KIDS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is OrthoPediatrics' stock price today?

One share of KIDS stock can currently be purchased for approximately $44.00.

How much money does OrthoPediatrics make?

OrthoPediatrics (NASDAQ:KIDS) has a market capitalization of $890.12 million and generates $98.05 million in revenue each year. The company earns $-16.26 million in net income (profit) each year or ($0.77) on an earnings per share basis.

How many employees does OrthoPediatrics have?

OrthoPediatrics employs 133 workers across the globe.

How can I contact OrthoPediatrics?

OrthoPediatrics' mailing address is 2850 Frontier Drive, Warsaw IN, 46582. The official website for OrthoPediatrics is www.orthopediatrics.com. The company can be reached via phone at (574) 268-6379, via email at [email protected], or via fax at 574-269-3692.

This page (NASDAQ:KIDS) was last updated on 6/29/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.